Among the explanations offered for how ibogaine works, the dopamine account is the most repeated. It usually runs along these lines: addiction depletes or dysregulates dopamine, and ibogaine resets the dopamine system, restoring it to a pre-addiction state. It is an appealing story because it is simple and because dopamine is the neurotransmitter most people associate with reward.

The difficulty is that when researchers measured dopamine directly after giving ibogaine, they found no change in the region the story depends on. This entry sets out that measurement, explains where the dopamine narrative actually comes from, and shows that the underlying research is about a growth factor rather than about dopamine levels.

The claim and the measurement

It is worth being precise about what a reset claim would require. It would require showing that dopamine signalling differs from normal in people with addiction, that ibogaine changes it, and that the change corresponds to clinical improvement. None of those three has been demonstrated in humans for ibogaine, and the second has been tested in animals with a negative result in the key region.

The general state of the field frames this. A 2026 review of three decades of human ibogaine research found that positive efficacy data come mostly from uncontrolled studies [5], and the 2019 pharmacology review states that the mechanism behind ibogaine's effect on drug-seeking remains unresolved [1]. A settled dopamine mechanism would be inconsistent with both statements.

There is also a problem with the premise. The idea that addiction consists of a depleted dopamine system which can be restored to a baseline is a simplification of a contested picture. Dopamine signalling in dependence involves changes in receptor density, in the timing of release, and in how strongly cues drive it, and those changes differ by substance and by stage. A single number that could be reset does not exist, which makes the reset framing difficult to cash out into a testable claim regardless of what any drug does.

The direct measurement

The relevant experiment used microdialysis in rats, a technique that samples neurotransmitter concentrations from a specific brain region in a living animal. Rats received intravenous ibogaine or noribogaine at 1 and 10 milligrams per kilogram, and dopamine and serotonin were measured in the nucleus accumbens alongside motor behaviour and plasma hormones [2].

Both compounds raised extracellular serotonin in the nucleus accumbens, and both inhibited serotonin uptake at the transporter, with noribogaine roughly ten times more potent than ibogaine as an indirect serotonin agonist. Both raised the stress hormones corticosterone and prolactin. Ibogaine produced dose-related tremor and noribogaine did not. And neither compound changed dopamine in the nucleus accumbens [2].

That last result is the one that bears on the popular claim. The nucleus accumbens is the structure at the centre of nearly every account of reward and addiction, and it is the region a dopamine reset story implicitly refers to. A direct measurement in a living animal found the drug did not move dopamine there, while it clearly did move serotonin. If anything in that experiment supports a neurotransmitter story, it is a serotonin story.

Two caveats apply in both directions. This is a rat study, and absence of change in one region at two doses does not exclude effects elsewhere or over longer timescales. But the same caveats would apply with equal force to a positive result, and the positive result is not the one that was obtained.

It is worth understanding what microdialysis does, because it is the most direct method available for this question. A fine probe is implanted in a chosen brain region of a living animal, fluid is slowly perfused through it, and neurotransmitters diffusing in from the surrounding tissue are collected and measured over time. It samples the extracellular concentration in that region while the animal is awake and behaving, which is as close as neuroscience gets to watching a neurotransmitter respond to a drug. When such a method reports no change, that is a measurement rather than an absence of data.

What binding the transporter means

Ibogaine does interact with the dopamine system in one documented way: it binds the dopamine transporter, the protein that clears dopamine from the synapse, at micromolar concentrations [1]. This is the factual basis most often cited in support of dopamine claims.

Binding a transporter is not the same as changing dopamine levels, and the microdialysis result shows why the distinction is not academic: the binding exists and the dopamine change did not appear [2]. The affinity is also in the micromolar range, meaning relatively weak, and a review of ibogaine's pharmacology describes it as interacting with transporters, opioid, sigma, glutamate and nicotinic receptors all at low micromolar concentrations, characterising it as a dirty drug [4].

If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.

Find a provider

Where the dopamine story comes from

The research that genuinely underlies most dopamine-related marketing is not about dopamine. It is about glial cell line-derived neurotrophic factor, or GDNF, a protein that supports the survival and function of dopamine-producing neurons. The connection to dopamine is indirect: GDNF acts on dopaminergic cells, so a change in GDNF is often described loosely as a change in the dopamine system.

GDNF is worth describing properly, since it carries most of the weight here. It is a protein that supports the survival, maintenance and function of neurons, with a particular role for dopamine-producing cells in the midbrain. The ventral tegmental area, where the clearest ibogaine effect was found, is one of the two main clusters of dopamine neurons in the brain and the origin of projections into the reward system. A sustained change in how those cells are supported is a plausible route to a lasting behavioural change, which is why the finding attracted attention.

The key experiment involved 36 male Wistar rats, six per group, given a single injection of ibogaine at 20 or 40 milligrams per kilogram or vehicle, with measurement at 3 and 24 hours. Only the 40 milligram dose raised GDNF, only at 24 hours, and only in two regions: a twelvefold increase in messenger RNA in the ventral tegmental area and a sixfold increase in the substantia nigra. A protein increase was confirmed in the ventral tegmental area alone, at roughly twofold. The 20 milligram dose changed GDNF nowhere [1].

Those specifics are what the evidence consists of, and they are considerably narrower than the claims built on them. The effect required the higher of two doses, appeared at one of two time points, reached protein level in one of several regions examined, and was observed in six animals per group. The review grades it as plausible, with no human confirmation [1].

A related finding in the same work is instructive about how such results get reported. Messenger RNA for a different growth factor, BDNF, rose enormously at 24 hours, by up to 340-fold in the nucleus accumbens, yet mature BDNF protein showed no significant increase in any region [1]. Pages stating that ibogaine increases BDNF are describing the transcript, not the protein, and in the study they draw on the protein did not move.

The study that tested the loop

One study went further than measuring GDNF and tested whether it was necessary for a behavioural effect. In rats, ibogaine at 40 milligrams per kilogram reduced ethanol intake in two-bottle choice and operant self-administration tests, and in a relapse model, while sucrose preference was unchanged, indicating the effect was not a general loss of appetite for rewards [3].

The same work measured midbrain GDNF messenger RNA in rats and mice, microinjected ibogaine directly into the ventral tegmental area and the substantia nigra, examined GDNF pathway signalling in a human neuroblastoma cell line, infused GDNF itself into the ventral tegmental area, and then infused GDNF-neutralising antibodies into the ventral tegmental area for two weeks. Blocking GDNF in that region weakened ibogaine's effect on drinking [3].

That is a well-designed causal experiment and the strongest mechanistic evidence in the area. It establishes that in rats, for alcohol intake, GDNF signalling in the ventral tegmental area is part of the pathway. It remains a rodent study about alcohol, and it is about a growth factor rather than dopamine concentrations.

One translation issue runs through all of this rodent work and is rarely mentioned. The GDNF effect required 40 milligrams per kilogram in rats, and the alcohol study used the same dose [1] [3]. Human treatment doses in published series are around 8 to 12 milligrams per kilogram. Doses do not translate between species on a simple weight basis, because metabolism scales differently, but the gap is large enough and in the direction that matters enough to be worth stating: the dose that produced the growth factor effect in rats was several times the human dose per kilogram, and the lower rat dose produced no GDNF change at all.

The self-sustaining loop hypothesis

The proposal that connects these findings to durable change is that ibogaine-induced GDNF triggers a self-sustaining loop, in which GDNF stimulates its own continued production and the cycle persists after the drug has cleared. That would resolve the central timing problem: a short-lived drug producing a long-lasting effect.

The 2019 review presents this as a hypothesis and nothing more, describing it as a new rationale rather than a finding [1]. It is an appealing idea precisely because it would explain what needs explaining, which is also a reason to be careful with it. Explanatory convenience is not evidence.

What it adds up to

Assembled honestly, the position is this. Ibogaine binds the dopamine transporter weakly. Direct measurement in rats found no change in nucleus accumbens dopamine. A single injection raised GDNF in rats at the higher of two doses, at one time point, in a dopamine-rich midbrain region. Blocking GDNF in that region reduced ibogaine's effect on alcohol drinking in rats. A self-sustaining GDNF loop has been proposed and not demonstrated. No human study has measured any of this.

That is a real and interesting body of work. It is not a dopamine reset, and the phrase misdescribes it in a way that happens to make the drug sound both better understood and more precisely targeted than it is. Anyone told that ibogaine resets their dopamine is being given a summary that the underlying papers do not support.

Frequently asked questions

Does ibogaine reset dopamine?

No study supports that. Direct microdialysis measurement in rats found neither ibogaine nor noribogaine changed dopamine in the nucleus accumbens, while both raised serotonin there [2].

So why do so many pages mention dopamine?

Because the underlying research concerns GDNF, a growth factor supporting dopamine-producing neurons, measured in rat midbrain [1]. A change in that growth factor is often loosely described as a change in dopamine.

How strong is the GDNF evidence?

In rats, reasonably strong for alcohol: blocking GDNF in the ventral tegmental area weakened ibogaine's effect on drinking [3]. The original upregulation finding used six animals per group, required the higher dose, and appeared at one time point [1]. There is no human confirmation.

Does the serotonin finding matter more?

On the direct evidence it is the clearer signal: both ibogaine and noribogaine raised extracellular serotonin in the nucleus accumbens and inhibited serotonin uptake, with noribogaine about ten times more potent [2]. It is still a rodent finding, and the same study recorded rises in corticosterone and prolactin alongside it.

Does ibogaine raise BDNF?

Messenger RNA rose up to 340-fold in rats, but mature BDNF protein showed no significant increase in any region [1]. Claims about BDNF generally refer to the transcript rather than the protein.

Safety. Ibogaine prolongs the heart's QT interval and can trigger dangerous arrhythmias. Treatment requires an EKG and bloodwork before dosing, continuous cardiac monitoring during, and medically trained staff present. Ibogaine is not safe to take unsupervised.
Disclaimer: This entry is general information, not medical advice.

References

  1. Marton S, Gonzalez B, Rodriguez-Bottero S, et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
  2. Baumann MH, Rothman RB, Pablo JP, Mash DC. 2001, J Pharmacol Exp Ther 297(2):531-539. PMID 11303040. europepmc.org/article/MED/11303040
  3. He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D. 2005, J Neurosci 25(3):619-628. doi:10.1523/JNEUROSCI.3959-04.2005. PMID 15659598. PMC1193648. europepmc.org/article/PMC/PMC1193648
  4. Koenig X, Hilber K. 2015, Molecules 20(2):2208-2228. doi:10.3390/molecules20022208. PMC4382526. mdpi.com/1420-3049/20/2/2208
  5. Kervadec E, Bezo A, Serreau R, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. doi.org/10.1097/jcp.0000000000002197